Literature DB >> 15133498

An activated mTOR mutant supports growth factor-independent, nutrient-dependent cell survival.

Aimee L Edinger1, Craig B Thompson.   

Abstract

In yeast, TOR couples cellular growth and metabolism to the availability of extracellular nutrients. In contrast, mammalian TOR kinase activity has been reported to be regulated by growth factor stimulation via the PI3K/Akt pathway. Consistent with this, growth factor deprivation results in dephosphorylation of the mTOR target proteins p70S6k and 4EBP1 in the face of abundant extracellular nutrients. To determine whether the activation of mTOR was sufficient to support cell survival in the absence of other growth factor-mediated signal transduction, we evaluated the ability of a growth factor-independent mTOR mutant, DeltaTOR, to protect cells from growth factor deprivation. DeltaTOR- but not wild-type mTOR-expressing cells were protected from many of the sequelae of growth factor deprivation including amino-acid transporter degradation, reduction of the glycolytic rate, cellular atrophy, decreased mitochondrial membrane potential, and Bax activation. Furthermore, DeltaTOR expression increased growth factor-independent, nutrient-dependent cell survival and enhanced the ability of p53-/- MEFs to form colonies in soft agar. These results suggest that activating mutations of mTOR can contribute to apoptotic resistance and might contribute to cellular transformation. Copyright 2004 Nature Publishing Group

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15133498     DOI: 10.1038/sj.onc.1207738

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  34 in total

Review 1.  mTOR at the crossroads of T cell proliferation and tolerance.

Authors:  Anna Mondino; Daniel L Mueller
Journal:  Semin Immunol       Date:  2007-03-23       Impact factor: 11.130

2.  Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

Authors:  James A McCubrey; Linda S Steelman; Richard A Franklin; Steven L Abrams; William H Chappell; Ellis W T Wong; Brian D Lehmann; David M Terrian; Jorg Basecke; Franca Stivala; Massimo Libra; Camilla Evangelisti; Alberto M Martelli
Journal:  Adv Enzyme Regul       Date:  2007-03-26

3.  Alterations of cellular bioenergetics in pulmonary artery endothelial cells.

Authors:  Weiling Xu; Thomas Koeck; Abigail R Lara; Donald Neumann; Frank P DiFilippo; Michelle Koo; Allison J Janocha; Fares A Masri; Alejandro C Arroliga; Constance Jennings; Raed A Dweik; Rubin M Tuder; Dennis J Stuehr; Serpil C Erzurum
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-16       Impact factor: 11.205

4.  Mitochondrial Extrusion through the cytoplasmic vacuoles during cell death.

Authors:  Akihito Nakajima; Hidetake Kurihara; Hideo Yagita; Ko Okumura; Hiroyasu Nakano
Journal:  J Biol Chem       Date:  2008-07-01       Impact factor: 5.157

5.  Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.

Authors:  James A McCubrey; Melissa L Sokolosky; Brian D Lehmann; Jackson R Taylor; Patrick M Navolanic; William H Chappell; Stephen L Abrams; Kristin M Stadelman; Ellis W T Wong; Negin Misaghian; Stefan Horn; Jörg Bäsecke; Massimo Libra; Franca Stivala; Giovanni Ligresti; Agostino Tafuri; Michele Milella; Marek Zarzycki; Andrzej Dzugaj; Francesca Chiarini; Camilla Evangelisti; Alberto M Martelli; David M Terrian; Richard A Franklin; Linda S Steelman
Journal:  Adv Enzyme Regul       Date:  2008-02-21

6.  Mitotic raptor promotes mTORC1 activity, G(2)/M cell cycle progression, and internal ribosome entry site-mediated mRNA translation.

Authors:  Francisco Ramírez-Valle; Michelle L Badura; Steve Braunstein; Manisha Narasimhan; Robert J Schneider
Journal:  Mol Cell Biol       Date:  2010-05-03       Impact factor: 4.272

7.  Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.

Authors:  Jianing Xu; Can G Pham; Steven K Albanese; Yiyu Dong; Toshinao Oyama; Chung-Han Lee; Vanessa Rodrik-Outmezguine; Zhan Yao; Song Han; David Chen; Daniel L Parton; John D Chodera; Neal Rosen; Emily H Cheng; James J Hsieh
Journal:  J Clin Invest       Date:  2016-08-02       Impact factor: 14.808

8.  Mutations in critical domains confer the human mTOR gene strong tumorigenicity.

Authors:  Avaniyapuram Kannan Murugan; Ali Alzahrani; Mingzhao Xing
Journal:  J Biol Chem       Date:  2013-01-15       Impact factor: 5.157

9.  Rab7 activation by growth factor withdrawal contributes to the induction of apoptosis.

Authors:  Kimberly Romero Rosales; Eigen R Peralta; Garret G Guenther; Susan Y Wong; Aimee L Edinger
Journal:  Mol Biol Cell       Date:  2009-04-22       Impact factor: 4.138

10.  Activating mutations in TOR are in similar structures as oncogenic mutations in PI3KCalpha.

Authors:  Thomas W Sturgill; Michael N Hall
Journal:  ACS Chem Biol       Date:  2009-12-18       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.